

Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 29 December 2017 (the “**Prospectus**”) issued by C-MER Eye Care Holdings Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The Shares may not be offered or sold in the United States except pursuant to an effective registration statement or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Shares in the United States.

This announcement is for information purpose only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company before deciding whether or not to invest in the Offer Shares.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Sock: 3309)

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on 7 February 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by China Merchants Securities (HK) Co., Limited, the Stabilizing Manager and the Sole Global Coordinator, or any person acting for it, during the stabilization period involved:

- (1) over-allocations of an aggregate of 29,550,000 Shares in the International Offering, representing 15% of the initial number of the Offer Shares;
- (2) borrowing of an aggregate of 29,550,000 Shares by China Merchants Securities (HK) Co., Limited from C-MER Group, a Controlling Shareholder, to cover the over-allocations in the International Offering; and
- (3) the full exercise of the Over-allotment Option by the Sole Global Coordinator on 18 January 2018 in respect of 29,550,000 additional new Shares issued and allotted by the Company at the Offer Price of HK\$2.90 to facilitate the return to C-MER Group of the 29,550,000 borrowed Shares which were used to settle the over-allocations in the International Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), that the stabilization period in connection with the Global Offering ended on 7 February 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by China Merchants Securities (HK) Co., Limited, the Stabilizing Manager and the Sole Global Coordinator, or any person acting for it, during the stabilization period involved:

- (1) over-allocations of an aggregate of 29,550,000 Shares in the International Offering, representing 15% of the initial number of the Offer Shares;
- (2) borrowing of an aggregate of 29,550,000 Shares by China Merchants Securities (HK) Co., Limited from C-MER Group, a Controlling Shareholder, to cover the over-allocations in the International Offering; and

- (3) the full exercise of the Over-allotment Option by the Sole Global Coordinator on 18 January 2018 in respect of 29,550,000 additional new Shares issued and allotted by the Company at the Offer Price, to facilitate the return to C-MER Group of the 29,550,000 borrowed Shares which were used to settle the over-allocations in the International Offering.

There had been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilizing Manager during the stabilization period.

Further details of the full exercise of the Over-allotment Option are set forth in the announcement of the Company dated 18 January 2018.

By order of the Board of Director
C-MER EYE CARE HOLDINGS LIMITED
Dr. LAM Shun Chiu Dennis JP
Chairman

Hong Kong, 7 February 2018

As of the date of this announcement, the executive Directors are Dr. LAM Shun Chiu Dennis JP, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan; the independent non-executive Directors are Dr. LAU Johnson Yiu-Nam, Dr. LI Kwok Tung Donald SBS JP, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.